The chronic obstructive pulmonary disease (COPD) therapy market continues to suffer from the absence of any agents that can reverse disease progression and repair lung tissue. Smoking cessation is the only way to slow or halt disease progression; therapies that can reverse pathological processes and regenerate alveolar tissue have yet to be discovered. In the absence of a truly disease-modifying therapy, inhaled bronchodilator therapies are usually prescribed, and drug development has focused on improving breathing or reducing inflammation. Although inhaled medications are primarily effective in reducing the burden of COPD by easing its symptoms, patients’ quality of life still suffers. Thus, significant unmet need remains for more-effective therapies, especially for patients with severe COPD.


  • What clinical and nonclinical attributes are key influencers to pulmonologists’ prescribing decisions, which have limited impact, and what are potential areas of hidden opportunity?
  • How do current therapies (e.g., Boehringer Ingelheim’s Spiriva, GlaxoSmithKline’s Advair /Seretide, AstraZeneca’s Symbicort, GSK / Innoviva’s Anoro, BI’s Stiolto / Spiolto, GSK’s Trelegy) perform on key treatment drivers and goals for COPD?
  • How do key clinical and nonclinical attributes impact pulmonologists’ preference for and likelihood to prescribe a hypothetical new COPD drug?


Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.

Markets covered: United States, United Kingdom, France, Germany

Primary research: Survey of 61 U.S. and 30 European pulmonologists fielded in February 2020

Key companies: GSK, Boehringer Ingelheim, AstraZeneca, Novartis

Key drugs: Spiriva, Advair / Seretide, Symbicort, Utibron / Ultibro, Anoro, Stiolto / Spiolto, Trelegy

Table of contents

  • Chronic Obstructive Pulmonary Disease - Unmet Need - Detailed, Expanded Analysis: Moderate To Severe (US/EU)

Author(s): Qinghui Yu, PhD

Qinghui Yu is a business insights analyst at Decision Resources Group. She has authored market research reports analyzing market trends in autoimmune diseases.

Prior to joining Decision Resources Group, Dr. Yu worked as a senior analyst for a life science consulting firm, where she worked on a range of projects providing strategic growth advice to clients in life science industries. Qinghui Yu holds a Ph.D. in Neuroscience from Columbia University.

Related Reports

Chronic Obstructive Pulmonary Disease - Landscape & Forecast - Disease Landscape & Forecast - 2020

The large therapeutic market for chronic obstructive pulmonary disease (COPD), a disease that is closely associated with smoking, continues to expand and is expected to grow from approximately $15...

View Details

Chronic Obstructive Pulmonary Disease - Current Treatment - Detailed, Expanded Analysis (US): Treatment Algorithms: Claims Data Analysis

Long-acting beta2agonist (LABA)/long-acting muscarinic antagonist (LAMA) fixed-dose...

View Details

Chronic Obstructive Pulmonary Disease - Access & Reimbursement - Detailed, Expanded Analysis (US) Inhaled COPD Therapies

Medicare beneficiaries with chronic obstructive pulmonary disease (COPD) have access to more than a dozen long-acting bronchodilator inhal...

View Details

Chronic Obstructive Pulmonary Disease | Disease Landscape and Forecast | G7 | 2019

Thechronic obstructive pulmonary disease(COPD) market is continuing its gradual shift away from long-acting beta2 agonist/inhaled corticos...

View Details